---
id: 073
title: Ganciclovir/Valganciclovir for CMV
category: antimicrobials
subcategory: antivirals_cmv
tags: [ganciclovir, valganciclovir, CMV, bone-marrow-suppression, retinitis]
difficulty: medium
---

## Question

What is ganciclovir's mechanism and major toxicity? Use the **"CMV UL97 + BONE Marrow"** mnemonic.

## Answer

### **"CMV UL97 + BONE Marrow" Mnemonic:**

**CMV UL97:**
- **C**MV-specific (acyclovir doesn't work)
- **M**echanism: inhibits viral DNA polymerase
- **V**alganciclovir = oral prodrug

**UL97:**
- **U**L97 kinase activates drug (CMV enzyme)
- **L**ike viral TK for acyclovir
- **9**0% bioavailability (valganciclovir)
- **7** days typical induction duration

**BONE Marrow:**
- **B**one marrow suppression (dose-limiting)
- **O**ccurs in 15-40%
- **N**eutropenia most common
- **E**specially with high doses

**Marrow:**
- **M**yelosuppression = major toxicity
- **A**NC <500 in 15-30%
- **R**eversible with G-CSF
- **R**equires CBC monitoring
- **O**ften dose-limiting
- **W**eekly CBC needed

### **Mechanism:**

1. **CMV UL97 kinase** phosphorylates ganciclovir (like viral TK)
2. Cellular kinases → ganciclovir triphosphate
3. Inhibits CMV **DNA polymerase**
4. Incorporated into viral DNA → chain termination

**Key:** Requires **CMV-specific UL97 enzyme** (why acyclovir doesn't work for CMV)

### **Indications:**

| Indication | Regimen | Duration |
|------------|---------|----------|
| **CMV retinitis (AIDS)** | Valganciclovir 900mg PO BID × 14-21d → 900mg daily | Lifelong (or until CD4>100) |
| **CMV colitis (transplant)** | Ganciclovir 5mg/kg IV q12h × 14-21d | 2-3 weeks |
| **CMV prophylaxis (transplant)** | Valganciclovir 900mg PO daily | 3-6 months post-transplant |

## Key Points

### **Major Toxicity: Myelosuppression**

**Incidence:**
- **Neutropenia:** 15-40% (ANC <1000), 15-30% (ANC <500)
- **Thrombocytopenia:** 5-15%
- **Anemia:** 5-10%

**Management:**
- **Weekly CBC** during induction, then every 2 weeks
- Hold if ANC <500, consider G-CSF
- Dose reduce if moderate cytopenias

### **Valganciclovir vs Ganciclovir:**

| Feature | Ganciclovir | Valganciclovir |
|---------|-------------|----------------|
| **Route** | IV only | **Oral** (prodrug) |
| **Bioavailability** | N/A | **60% (with food)** |
| **Dosing** | 5mg/kg IV q12h | 900mg PO BID |
| **Use** | Severe CMV disease | Mild-moderate, prophylaxis |

**Pearl:** Valganciclovir converted to ganciclovir by intestinal/hepatic esterases

### **Resistance: UL97 Mutations**
- Mutations in **UL97 kinase** → no phosphorylation
- Less common: DNA polymerase mutations
- **Foscarnet** for resistant CMV (bypasses UL97)

### **Clinical Pearls:**
- **Oral valganciclovir** as effective as IV ganciclovir for most indications
- **Bone marrow suppression** is dose-limiting (monitor CBC weekly)
- **NOT effective for HSV/VZV** (lacks viral TK)
- Take valganciclovir **with food** (↑ absorption)

## Sources

- [StatPearls: Ganciclovir]
- [Transplant Guidelines: CMV Management]

## Media

N/A
